Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

4(44.4%)

Phase 3

2(22.2%)

Phase 4

1(11.1%)

N/A

1(11.1%)

Phase 1

1(11.1%)

9Total

Phase 2(4)

Phase 3(2)

Phase 4(1)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT07285070Phase 2Recruiting

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

Role: lead

NCT06329661Phase 4Completed

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

Role: lead

NCT04523142Phase 3Completed

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

Role: lead

NCT04523129Phase 3Completed

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Role: lead

NCT03292809Phase 2Completed

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Role: lead

NCT03333057Phase 2Completed

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Role: lead

NCT04521465Completed

Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye

Role: lead

NCT02617667Phase 2Completed

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

Role: lead

NCT03048526Not ApplicableCompleted

Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease

Role: lead

NCT02356328Completed

NovaTears® Eye Drops Observational Study NT-003

Role: lead

NCT02356341Completed

NovaTears® Eye Drops Observational Study NT-002

Role: lead

NCT02111928Completed

NovaTears® Eye Drops Observational Study

Role: lead

NCT02113293Phase 1Completed

CyclASol® Phase 1 Study

Role: lead

All 13 trials loaded